• argenx enters into agreement to acquire priority review voucher

    Wednesday November 30th 2022

  • Monkeys not Donkeys, QbD Group’s life science marketing and communication agency, strengthens its team

    Monday November 28th 2022

  • Ghent start-up Protealis accelerates local soybean development

    Friday November 25th 2022

  • VIB researchers identify a new way of supporting and sensitizing immunotherapy in cancer patients

    Friday November 25th 2022

  • Oxurion further improves THR-149 patent position

    Thursday November 24th 2022

  • Pathomation releases an updated version PMA.transfer to easily manipulate whole slide images in digital pathology and virtual microscopy

    Tuesday November 22nd 2022

  • Nathalie Draux succeeds Philippe Draux as CEO of Quality Assistance

    Tuesday November 22nd 2022

  • argenx announces U.S. FDA acceptance of biologics license application for subcutaneous efgartigimod in generalized myasthenia gravis with priority review

    Tuesday November 22nd 2022

  • Your news here?

  • Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023

    Monday November 21st 2022

  • BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma

    Thursday November 17th 2022

  • Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia

    Tuesday November 15th 2022

Strategic Partners